Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | TSC2 |
| Variant | F1668L |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | TSC2 F1668L lies within the Rap-GAP domain of the Tsc2 protein (UniProt.org). F1668L results in protein stability and inhibition of mTORC1 signaling similar to wild-type Tsc2 in cultured cells but results in a loss of catalytic activity in an in vitro assay (PMID: 32502382), and therefore, is predicted to lead to a loss of Tsc2 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
TSC2 mutant TSC2 inact mut TSC2 F1668L |
| Transcript | NM_000548.5 |
| gDNA | chr16:g.2087875T>C |
| cDNA | c.5002T>C |
| Protein | p.F1668L |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000548.4 | chr16:g.2087875T>C | c.5002T>C | p.F1668L | RefSeq | GRCh38/hg38 |
| NM_000548.5 | chr16:g.2087875T>C | c.5002T>C | p.F1668L | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|